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Background: M1 gastric cancer has a poor oncologic outcome with a median survival of less than 1 year despite
aggressive chemotherapy. Recent trials include chemotherapy combined non-curative gastrectomy. This study
evaluated the chemoresponse after non-curative gastrectomy in M1 gastric cancer and the survival benefit.
Methods: Between January 2000 and December 2010, 660 patients received chemotherapy for gastric cancer at
the Department of Hemato-Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu,
Korea. Data was collected retrospectively from the medical records. Patients who received preoperative or adjuvant
chemotherapy, who underwent other surgeries like gastrojejunal bypass or exploratory laparotomy, who died within
3 months due to seriously advanced gastric cancer, who were lost to follow-up, or whose medical records were
unsuitable for data collection were excluded. The remaining 101 patients had received chemotherapy only (CTx group,
n = 76) or chemotherapy after non-curative gastrectomy (NCG + CTx group, n = 25). Clinicopathologic characteristics,
chemoresponse, and overall survival were compared between the two groups.
Results: There were no significant differences between the two groups in clinicopathologic characteristics including
age, sex, body mass index (BMI), comorbidity, histologic differentiation, tumor location, clinical T stage, and
initial site of distant metastasis. Chemoresponse was checked on two separate occasions from the initiation of
chemotherapy: first chemotherapy regimen and until the third regimen change. The NCG + CTx group showed
more favorable chemoresponse than the CTx group in both checks (60% and 72% vs. 18.4% and 23.7%). The
NCG + CTx group showed longer overall survival than the CTx group (26 vs. 11 months).
Conclusions: Non-curative gastrectomy in M1 gastric cancer could improve chemoresponse and extend overall
survival.
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M1 gastric cancer is characterized by distant metastasis at
sites other than regional lymph node (LN) [1]. Distant me-
tastasis comprises peritoneal metastasis including ovarian
metastasis; hematogenous metastasis that spreads to the
liver, lung, and bone; and metastasis to distant LNs includ-
ing paraaortic, neck, and mediastinal LNs.
Chemotherapy has been recommended as a main
treatment modality for M1 gastric cancer in the third
Japanese gastric cancer treatment guidelines as well as in
the 2013 National Comprehensive Cancer Network
(NCCN) gastric cancer guidelines [2,3]. However, the* Correspondence: sohnss@dsmc.or.kr
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despite aggressive chemotherapy. Although a few clinical
trials showed the effectiveness of adjuvant chemotherapy
after curative resection in advanced gastric cancer [4-7],
the generally poor oncologic outcomes in M1 gastric
cancer might be caused by the lack of an outstanding
chemotherapeutic agent and definite treatment guide-
lines specifying surgery [8].
Several study groups have tried to improve the onco-
logic outcomes with the various new concepts including
liver resection for hepatic metastasis from gastric cancer,
aggressive surgery with peritonectomy for localized peri-
toneal metastasis, intraperitoneal chemotherapy, surgeryis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vorable response after chemotherapy, and chemotherapy
after non-curative gastrectomy. Some survival benefits
were reported [9-24]. But these studies focused on pa-
tient survival, although chemoresponse could be the
most important mechanism to prolong the survival time
after chemotherapy.
With this in mind, we concentrated our attention on
the chemoresponse after non-curative gastrectomy in
M1 gastric cancer. We hypothesized that non-curative
gastrectomy will improve the chemoresponse by redu-
cing tumor burden, similar to other cancers, with non-
curative gastrectomy inhibiting the chemoresponse by
destroying the lymphatic channels or blood vessels that
are the anatomic routes to tumor. Accordingly, the goalFigure 1 Study design.was to identify if non-curative gastrectomy could im-
prove the chemoresponse. The influence of chemore-
sponse on patient survival was assessed.
Methods
Between January 2000 and December 2010, 660 patients
received chemotherapy for gastric cancer at the Depart-
ment of Hemato-Oncology, Dongsan Medical Center,
Keimyung University School of Medicine, Daegu, Korea.
We collected the data from this group through a retro-
spective review of medical records. Patients who re-
ceived preoperative or adjuvant chemotherapy, who
underwent other surgeries like gastrojejunal bypass or
exploratory laparotomy, who died within 3 months due
to seriously advanced gastric cancer, and who were lost






Age, years Mean (SD) 53.7 (±10.9) 54.3 (±11.0) >0.05
Sex Male 54 (71.1%) 18 (72.0%) >0.05
Female 22 (28.9%) 7 (28.0%)
BMI, kg/m2 Mean (SD) 22.0 (±3.2) 21.8 (±2.2) >0.05
Comorbidity Yes 14 (18.4%) 6 (24.0%) >0.05
Histology Differentiated 17 (22.4%) 7 (28.0%) >0.05
Undifferentiated 59 (77.6%) 18 (72.0%)
Tumor location Upper 11 (14.5%) 7 (28.0%) >0.05
Middle 13 (17.1%) 1 (4.0%)
Lower 39 (51.3%) 13 (52.0%)
Entire 13 (17.1%) 4 (16.0%)
cT stage T1 ~ 3 7 (9.2%) 7 (28.0%) <0.05
T4 69 (90.8%) 18 (72.0%)
Initial M1 site Peritoneal 19 (25.0%) 15 (60.0%) <0.01
Hematogenous 15 (19.7%) 5 (20.0%)
Distant LN 24 (31.6%) 2 (8.0%)
Mixed 18 (23.7%) 3 (12.0%)
Abbreviation: cT stage clinical T stage, SD standard deviation.
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data collection were excluded (Figure 1). The remaining
101 patients had received chemotherapy only (CTx
group, n = 76) or chemotherapy after non-curative gas-
trectomy (NCG + CTx group, n = 25). Non-curative gas-
trectomies were comprised of total gastrectomy (n = 15)
and subtotal gastrectomy (n = 10).
There were no significant differences between the two
groups in clinicopathologic characteristics including age,
sex, body mass index (BMI), comorbidity, histologic dif-
ferentiation, tumor location, clinical T stage, and initial
site of distant metastasis (Table 1). Chemoresponse and
overall survival were compared. In the absence of pre-
viously defined criteria for chemoresponse, new criteria
were assigned (Figure 2). Patients presenting once withFigure 2 Reclassification of chemoresponse according to the Responscomplete response (CR) or partial response (PR) or stable
disease (SD) on the Response Evaluation Criteria in Solid
Tumors (RECIST) according to clinical progress and
follow-up computed tomography (CT), positron emission
tomography (PET), bone scan, or magnetic resonance im-
aging (MRI) from initiation of chemotherapy to the time
of evaluation were reclassified as ‘favorable chemore-
sponse.’ Otherwise, patients who continued to present
progressive disease (PD) until evaluation were reclassified
as ‘unfavorable chemoresponse’. The clinical course of pa-
tients who received palliative chemotherapy for M1 gastric
cancer is typically determined following the third change
of regimen. Thus, chemoresponse was checked on two
separate occasions from the initiation of chemotherapy.
One was chemoresponse for the first chemotherapy regi-
men. The other was chemoresponse until the third regi-
men change. Overall survival between the two groups was
compared. Various regimens were applied for the first
chemotherapy as shown in Table 2.
This study was approved by the Institutional Review
Board of Keimyung University School of Medicine,
Dongsan Medical Center, Daegu, Korea (IRB file no.
2014-01-018).
Statistical analyses
SPSS version 20.0 (SPSS, Chicago, IL, USA) was used for
statistical analyses. To compare the clinicopathologic
characteristics and the chemoresponse between the two
groups, chi-square test was used for categorical vari-
ables, and Student’s t-test and Fisher’s exact test were
used for continuous variables. Overall survival was ana-
lyzed with the Kaplan-Meier curve analysis, and statistical
significance was evaluated with log-rank test. P < 0.05 was
considered significant.
Results
There were no significant differences in age, sex, BMI,
comorbidity, histologic differentiation, and tumor loca-
tion between the two groups (Table 1). Despite efforts to
make the two groups homogenous, clinical T4 gastrice Evaluation Criteria in Solid Tumor (RECIST).







For the first regimen Favorable 14 (18.4%) 15 (60.0%) <0.01
Unfavorable 62 (81.6%) 10 (40.0%)
Until the third regimen Favorable 18 (23.7%) 18 (72.0%) <0.01
Unfavorable 58 (76.3%) 7 (28.0%)
Table 4 Overall survival
Group Median
(months)
1-YSR (%) 2-YSR (%) 3-YSR (%) P value
CTx 11 40.6 16.1 4.8 <0.01
NCG + CTx 26 83.4 57.1 35.6
Abbreviation: YSR year survival rate.







Paclitaxel/cisplatin/TS-1 27 24 3
Paclitaxel/cisplatin 21 21
Capecitabine/cisplatin 9 2 7
FOLFOX (folinic acid/5-FU/oxaliplatin) 7 2 5
Paclitaxel/TS-1 6 5 1
Irinotecan/cisplatin 5 4 1
Docetaxel/oxaliplatin 5 4 1
5-FU/cisplatin 4 3 1
Heptaplatin/5-FU 4 4









Abbreviations: 5-FU 5-fluorouracil, MMC mitomycin-C, TS-1 tegafur-gimeracil-oteracil
potassium.
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However, considering that serosal exposure of gastric
cancer could not be identified directly in this group be-
cause there was no operative view and it was difficult to
distinguish T4 from T3 in gastric cancer by CT and PET,
this slight difference was disregarded.
The NCG + CTx group displayed a higher proportion
of peritoneal metastasis than the CTx group (60.0% vs.
25.0%). Distant LN metastasis was more common in the
CTx group (31.6% vs. 8.0%). If we regarded the existence
of mixed-type metastasis as being indicative of the ag-
gressiveness of M1 gastric cancer, there was no signifi-
cant difference in the aggressiveness of cancer between
the two groups, because the mixed type metastasis be-
tween the two groups displayed no significant difference
(23.7% vs. 12%, P = 0.266).
Based on this result, we compared the chemore-
sponse and overall survival. The NCG + CTx group
showed more favorable chemoresponse than the CTx
group at both checks (60% and 72% vs. 18.4% and
23.7%; Table 3). The NCG + CTx group had a longer
overall survival than the CTx group (26 vs. 11 months;
Table 4, Figure 3).
Discussion
Presently, patients who received chemotherapy after non-
curative gastrectomy for M1 gastric cancer displayed amore favorable chemoresponse and longer overall sur-
vival. This result is consistent with the view that non-
curative gastrectomy in M1 gastric cancer improves the
chemoresponse by reducing the tumor burden [25,26],
with minimal inhibited chemoresponse due to destruction
of the anatomic route to the tumor during surgery, which
lead to prolonged overall survival.
Several previous studies reported that various non-
curative surgeries that reduce the tumor burden could
produce a survival benefit in M1 gastric cancer [24,27-29].
However, the studies addressed survival after non-curative
surgery and not chemoresponse. The significance of the
present study was the focus on the relationship between
non-curative gastrectomy and chemoresponse.
Generally, it is anticipated that a more favorable che-
moresponse after chemotherapy could lead to longer
survival. However, how the chemoresponse could influ-
ence patient survival in M1 gastric cancer is unclear
[30]. This unreliable probability between chemoresponse
and survival in M1 gastric cancer might be caused by
the lack of an outstanding chemotherapeutic agent. With
the development of such an agent, studies demonstrating
the oncologic benefit of non-curative gastrectomy would
be an important cornerstone for the treatment guideline
for M1 gastric cancer.
This study has some limitations. The study was retro-
spective and the CTx group had no operative view,
which could create selection bias and heterogeneity be-
tween the two groups. Second, non-curative gastrectomy
in itself reduces the tumor burden, which could have
overestimated a favorable response. Third, the CTx
group displayed marginally more prevalent clinical T4
gastric cancer, which could be connected to poorer
survival. This lack of homogeneity should be consid-
ered in overall survival comparative analysis between
the two groups. Finally, a quality-of-life evaluation was not
Figure 3 Comparison of overall survival between the NCG + CTx group and the CTx group.
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mend non-curative gastrectomy, although it is feasible
technically.
Conclusions
Despite the aforementioned limitations due to the hetero-
geneity between the two groups, non-curative gastrectomy
in M1 gastric cancer could improve chemoresponse and
extend survival.
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